--- title: TRX Suspension Training for Sarcopenia in Older Men nct_id: NCT07398092 overall_status: COMPLETED phase: NA sponsor: WeiJin Zhang study_type: INTERVENTIONAL primary_condition: Sarcopenia countries: China canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07398092.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07398092" ct_last_update_post_date: 2026-02-12 last_seen_at: "2026-05-12T07:20:19.785Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # TRX Suspension Training for Sarcopenia in Older Men **Official Title:** Effects of TRX Suspension Training on Physical Fitness, Gait Performance, and Inflammatory and Growth-Related Biomarkers in Older Men With Sarcopenia: A Randomized Controlled Trial **NCT ID:** [NCT07398092](https://clinicaltrials.gov/study/NCT07398092) ## Key Facts - **Status:** COMPLETED - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 36 - **Lead Sponsor:** WeiJin Zhang - **Conditions:** Sarcopenia - **Start Date:** 2024-02-01 - **Completion Date:** 2024-08-30 - **CT.gov Last Update:** 2026-02-12 ## Brief Summary This randomized controlled trial evaluated the effects of a 12-week TRX suspension training program on physical fitness, gait performance, and selected blood biomarkers in older men with sarcopenia. Sarcopenia is an age-related condition characterized by loss of muscle mass, muscle strength, and physical function, which increases the risk of falls, disability, and reduced quality of life. A total of 36 older men diagnosed with sarcopenia were randomly assigned to either a TRX suspension training group or a control group. The training group participated in supervised TRX exercise sessions three times per week for 12 weeks, with each session lasting approximately 60 minutes. The control group maintained their usual daily activities without structured exercise intervention. Physical fitness, walking ability, and blood biomarkers related to inflammation and muscle growth were assessed before and after the intervention. The study aimed to determine whether TRX suspension training is a safe and effective exercise approach for improving muscle strength, balance, walking ability, and biological indicators associated with sarcopenia in older adults. ## Detailed Description This study was a single-center, randomized controlled trial designed to examine the effects of TRX suspension training on physical fitness, gait performance, and inflammatory- and growth-related biomarkers in older men with sarcopenia. Eligible participants were men aged 65 years and older who met established diagnostic criteria for sarcopenia based on low handgrip strength, reduced skeletal muscle mass index, and slow gait speed. After screening, 36 participants were randomly allocated in a 1:1 ratio to either an experimental group receiving TRX suspension training or a control group maintaining usual daily activities. The intervention consisted of a 12-week TRX suspension training program conducted three times per week. Each training session lasted approximately 60 minutes and included a warm-up period, a main training phase, and a cool-down period. The exercise program emphasized multi-joint, whole-body movements targeting the upper limbs, lower limbs, and trunk. Training intensity and difficulty were progressively adjusted using body angle and support-point principles to ensure safety and individualized progression for older participants. Assessments were performed before the intervention and within 48 hours after completion of the 12-week program. Outcome measures included physical fitness tests (upper- and lower-limb muscle strength, balance, and agility), gait performance tests (mobility, walking speed, and walking endurance), and fasting blood biomarkers related to inflammation and muscle growth, including interleukin-6, tumor necrosis factor-alpha, insulin-like growth factor-1, C-reactive protein, and vitamin D. The primary objective of the study was to determine whether TRX suspension training could improve muscle strength and functional mobility in older men with sarcopenia. Secondary objectives included evaluating changes in gait performance and selected biological markers associated with inflammation and muscle metabolism. This study aimed to provide evidence supporting the use of TRX suspension training as a safe and effective exercise strategy for improving physical function and reducing fall risk in older adults with sarcopenia. ## Eligibility - **Minimum age:** 65 Years - **Sex:** MALE - **Healthy Volunteers:** No ``` Inclusion Criteria: * Male participants aged 65 years or older. * Diagnosis of sarcopenia based on established criteria, including low handgrip strength, reduced skeletal muscle mass index, and slow gait speed. * Ability to walk independently without assistive devices. * Ability to understand the study procedures and provide written informed consent. * Willingness to participate in the 12-week intervention and complete all required assessments. Exclusion Criteria: * Presence of severe cardiovascular disease or other medical conditions that contraindicate moderate-intensity exercise. * Diagnosis of severe depression, dementia, or other neurological or psychiatric disorders that could interfere with participation. * Participation in other structured exercise or training programs during the study period. * History of drug or alcohol abuse. * Any musculoskeletal, neurological, or systemic condition that would prevent safe participation in the exercise intervention. ``` ## Arms - **TRX Suspension Training Group** (EXPERIMENTAL) — Participants assigned to this arm received a supervised TRX suspension training program for 12 weeks. Training sessions were conducted three times per week, with each session lasting approximately 60 minutes. The program included progressive, whole-body resistance exercises targeting the upper limbs, lower limbs, and trunk. - **Control Group** (OTHER) — Participants in the control group maintained their usual daily activities throughout the 12-week study period and did not participate in any structured exercise or training intervention. ## Interventions - **TRX Suspension Training** (BEHAVIORAL) — TRX suspension training was delivered as a structured, supervised exercise program conducted three times per week for 12 weeks. Each session lasted approximately 60 minutes and included warm-up, main training, and cool-down phases. The program emphasized progressive, whole-body resistance exercises targeting the upper limbs, lower limbs, and trunk, with training intensity individualized through adjustments in body angle and support points. - **Usual Daily Activities** (OTHER) — Participants continued their usual daily activities during the 12-week study period and did not receive any structured exercise or training intervention. ## Primary Outcomes - **Change in Handgrip Strength** _(time frame: Baseline to 12 weeks)_ — Handgrip strength was measured using a digital handgrip dynamometer. The primary outcome was the change in maximal handgrip strength from baseline to the end of the 12-week intervention period. ## Secondary Outcomes - **Change in 30-Second Chair Stand Test Performance** _(time frame: Baseline to 12 weeks)_ - **Change in 30-Second Arm Curl Test Performance** _(time frame: Baseline to 12 weeks)_ - **Change in Single-Leg Stance Time** _(time frame: Baseline to 12 weeks)_ - **Change in Four Square Step Test Performance** _(time frame: Baseline to 12 weeks)_ - **Change in Timed Up and Go Test Performance** _(time frame: Baseline to 12 weeks)_ - **Change in 10-Meter Walk Test Performance** _(time frame: Baseline to 12 weeks)_ - **Change in Six-Minute Walk Test Distance** _(time frame: Baseline to 12 weeks)_ - **Change in Serum Interleukin-6 Levels** _(time frame: Baseline to 12 weeks)_ - **Change in Serum Tumor Necrosis Factor-Alpha Levels** _(time frame: Baseline to 12 weeks)_ - **Change in Serum Insulin-Like Growth Factor-1 Levels** _(time frame: Baseline to 12 weeks)_ - **Change in Serum Vitamin D Levels** _(time frame: Baseline to 12 weeks)_ ## Locations (1) - Yibin University, Yibin, Sichuan, China ## Recent Field Changes (last 30 days) - `eligibility.sex` — added _(2026-05-12)_ - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.yibin university|yibin|sichuan|china` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT07398092.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT07398092* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*